AUS
NZ
UK
CA
USA
IND
Highlights:
- SNG001 Trial Preparations: Synairgen has completed the design for a phase II trial and optimised aerosol delivery for ventilator patients.
- Funding Requirements: Additional capital is needed to initiate the large-scale study, with updates expected soon.
- Financial Position: Synairgen reported a reduced loss of £3.7 million and closed the first half with £8.6 million in cash reserves.
Synairgen PLC (LSE:SNG) reported significant progress in preparations for a phase II trial of its lead drug candidate, SNG001, aimed at treating high-risk patients with severe viral lung infections. The company’s focus is on patients requiring ventilation, which CEO Richard Marsden said is strategically optimal for both clinical outcomes and potential market impact.
The company announced that it has finalised the design for the upcoming study and has successfully optimised the aerosol delivery system of SNG001, ensuring efficient administration through ventilator circuits. In parallel, Synairgen has engaged with a specialised clinical research organisation to support the execution of the trial, reflecting its commitment to a robust clinical evaluation.
However, Marsden noted that initiating this large-scale study will require additional funding, and the company plans to provide further updates as funding plans are finalised.
The interim financial results highlighted that Synairgen recorded a reduced loss of £3.7 million for the six months ending June 30, with £2.5 million allocated specifically to research and development activities. The company’s financial position remains stable, with £8.6 million in cash reserves at the period’s end, positioning it well for the next phase of SNG001’s clinical development.
Marsden expressed confidence in the company’s strategy, stating, “Having closely analysed various routes forward, we believe our focus on these high-risk patients is optimal from both a clinical and commercial perspective.”
